模拟简化肝脏MRI联合CT在直肠癌分期中筛查肝转移的表现
回顾性模拟图像阅片研究纳入476例直肠癌患者,比较单独CT、CT联合非增强简化MRI(NE-AMRI)及CT联合肝胆期简化MRI(HBP-AMRI)筛查肝转移的效能。CT+NE-AMRI敏感度高于单独CT(96.5% vs 86.8%,p<0.001),与CT+HBP-AMRI相似(p=0.54),三者特异度无显著差异。
要点
- CT+NE-AMRI筛查肝转移敏感度96.5%,高于单独CT的86.8%(p<0.001)。
- CT+NE-AMRI与CT+HBP-AMRI敏感度无显著差异(96.5% vs 96.9%,p=0.54)。
- 三种方案特异度无显著差异(p≥0.24)。
核心结论
- 基于回顾性模拟图像阅片,CT+NE-AMRI筛查肝转移的敏感度高于单独CT,且特异度未降低;将肝脏NE-AMRI整合入直肠癌常规盆腔MRI方案可能在不增加成本的情况下提高肿瘤分期准确性。
研究设计与样本
- 回顾性研究,纳入2017年至2022年在一家三级机构诊断为直肠癌的患者476例,使用全方案肝脏MRI模拟简化MRI,由两名阅片者独立评估。
临床应用与阅片要点
- 将肝脏NE-AMRI整合入直肠癌患者常规盆腔MRI方案可能提高肿瘤分期准确性且不增加成本;NE-AMRI每患者估计成本为$126.81/₩197,409,当前指南方案为$131.92/₩199,156。
局限性
- 本研究为回顾性模拟图像阅片研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Since non-enhanced pelvic MRI is routinely performed for staging rectal cancer, an additional scan of the liver during pelvic MRI could be easily acquired. This study aimed to evaluate the potential utility of routinely adding non-enhanced abbreviated MRI (NE-AMRI) for liver metastasis screening, in comparison to CT alone (the current guideline-recommended modality), and CT combined with AMRI using hepatobiliary phase imaging (HBP-AMRI) (another potential alternative).
MATERIALS AND METHODS: This retrospective study included patients diagnosed with rectal cancer between 2017 and 2022 at a tertiary institution. AMRI was simulated using full-protocol liver MRI. Two readers independently evaluated the presence of liver metastasis using (1) CT alone, (2) CT + NE-AMRI, and (3) CT + HBP-AMRI. Per-patient sensitivity and specificity for liver metastasis were compared using generalized estimating equations. The imaging cost of incorporating NE-AMRI was assessed using reimbursement data and the literature.
RESULTS: A total of 476 patients (mean age 61.3 ± 11.9 years; 302 males) were included, 144 (30.3%) of whom had liver metastasis. CT + NE-AMRI had sensitivity higher than CT alone (96.5% [92.6-98.4%] vs 86.8% [81.0-91.1%]; p < 0.001), and similar to CT + HBP-AMRI (96.9% [93.8-98.5%]; p = 0.54). No significant difference was noted in specificity between the three protocols (p ≥ 0.24). The cost incurred by incorporating NE-AMRI was estimated as $126.81/₩197,409 per patient, in comparison to $131.92/₩199,156 using the current guideline.
CONCLUSIONS: Based on a retrospective simulated image review, CT + NE-AMRI showed higher sensitivity for liver metastasis screening than CT alone, without a reduction in specificity. Integrating NE-AMRI of the liver into the routine pelvic MRI protocol in rectal cancer patients may improve tumor staging accuracy without added cost.
KEY POINTS: Question Can NE-AMRI added to rectal cancer staging enhance the diagnosis of liver metastasis without increasing cost? Findings Compared to using the current guideline, incorporating NE-AMRI yielded a higher sensitivity (96.5% vs 86.8%; p < 0.001) without significant difference in specificity or increased cost (estimated as $126.81 vs $131.92 per patient). Clinical relevance Since non-enhanced pelvic MRI is routinely performed for rectal cancer, additional scanning of the liver can be easily acquired during pelvic MRI. Adding non-enhanced abbreviated liver MRI for rectal cancer staging may improve sensitivity in detecting metastasis without added cost.
引用
- Heo S, Kim HY, Kim S, et al. Performance of simulated abbreviated liver MRI combined with CT for liver metastasis screening in rectal cancer staging. Eur Radiol. 2025. PMID: 40715681. doi:10.1007/s00330-025-11876-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。